Hospital stocks rise after 30% cap on anti-cancer drug margins
In short
Hospital stocks rose after the government capped trade margins on non-scheduled anti-cancer drugs at 30%. The report says prices could fall 20% to 70% and patients could save ₹2,500 crore a year.
Brokerages think the earnings hit may be manageable, but they warn hospital margins could still face pressure. The story does not say how long the price effect will last or which hospitals will be hit most.
What the reporting says
Hospital stocks including Fortis Healthcare, Apollo Hospitals, Max and Medanta rose after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, according to the market summary. The report says this could cut prices by 20% to 70% and save patients ₹2,500 crore a year. Brokerages said the earnings hit may be manageable, but hospital margins could still come under pressure.
Why it matters
Hospital shares, including Fortis Healthcare, Apollo Hospitals, Max and Medanta, rallied after the government capped trade margins on non-scheduled anti-cancer drugs at 30%. The summary says that could lower prices by 20% to 70% and save patients ₹2,500 crore annually. Brokerages see manageable earnings effects overall, but the source warns that hospital margins may come under pressure.